ImmunoGen (IMGN) Misses Q3 EPS by 2c; CFO Comments on Outlook
Tweet Send to a Friend
ImmunoGen, Inc. (NASDAQ: IMGN) reports a Q3 loss of $0.22, 2 cents worse than the analyst estimate of ($0.20). Revenue ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
